High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm

Clinical Infectious Diseases

Volumn 37, Issue 6, 2003, Pages 752-760

  Dunbar, Lala M ^a   Wunderink, Richard G ^b   Habib, Michael P ^c   Smith, Leon G ^d   Tennenberg, Alan M ^e   Khashab, Mohammed M ^e   Wiesinger, Barbara A ^e   Xiang, Jim X ^e   Zadeikis, Neringa ^e   Kahn, James B ^e  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b METHODIST UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d ST MICHAEL S MEDICAL CENTER   (United States)

^e Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SENSITIVITY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; VOMITING;

ADULT; ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PNEUMONIA; TREATMENT OUTCOME;

EID: 0141676184     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/377539     Document Type: Article

References (28)

1. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333:1618-24.
2. Bartlett JG, Dowell SF, Mandell LA, et al. Guidelines from the Infectious Diseases Society of America: practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31:347-82.
3. Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch Intern Med 1997; 157:1709-18.
4. Guthrie R. Community-acquired lower respiratory tract infections: etiology and treatment. Chest 2001; 120:2021-34.
5. Aranciba A, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa. Arch Intern Med 2002; 162:1849-58.
6. Doern G, Brueggermann A, Holley HJ, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40:1208-13.
7. Sahm DF, Thornsberry C, Jones ME, et al. Correlations of antimicrobial resistance among Streptococcus pneumoniae in the US: 2001-2002 TRUST surveillance [poster C2-1640]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
8. Blaser J, Stone BB, Groner MC, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31:1054-60.
9. Drusano GL, Johnson DE, Rosen M, et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37:483-90.
10. Forrest A, Dix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-81.
11. Preston SL, Drusano GL, Berman AL, et al. Prospective development of pharmacodynamic relationships between measures of levofloxacin exposure and measures of patient outcome: a new paradigm for early clinical trials. JAMA 1998; 279:125-9.
12. Fine MJ, Auble, TE, Yealy MD, et al. A prediction rule to identify low-risk subjects with community-acquired pneumonia. N Engl J Med 1997; 336:243-50.
13. Murray PR, Washington JA. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin Proc 1975; 50:339-44.
14. Levaquin (levofloxacin) [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, 2003.
15. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41:1965-72.
16. Fogarty CM, Sullivan JG, Chattman MS, et al. Once a day levofloxacin in the treatment of mild to moderate and severe community-acquired pneumonia in adults. Infect Dis Clin Pract 1998; 7:400-7.
17. Kahn J, Wiesinger B, Drucker L, et al. Cumulative clinical trial experience with levofloxacin in community-acquired pneumonia-associated pneumococcal bacteremia [poster 8.21]. In: Program and abstracts of the 6th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones. Atlanta: Wallace Communications, 2002.
18. Gotfried MH. Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: results from the 1999-2000 Respiratory Surveillance Program. Am J Med 2001; 111(Suppl 9A):25S-29S.
19. Pfaller MA, Ehrhardt AF, Jones RN. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the Respiratory Surveillance Program: microbiology from the medical office practice environment. Am J Med 2001; 111(Suppl 9A):4S-12S.
20. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002; 34(Suppl 1):S4-S16.
21. Lister PD. Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002; 44:43-9.
22. Gotfried MH, Danzinger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001; 119:1114-22.
23. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28:352-64.
24. Carbon C. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy 2001; 47(Suppl 3):9-14.
25. Chien S-C, Wong FA, Fowler CL, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 1998; 42:885-8.
26. Chow AT, Fowler C, Williams RR, et al. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother 2001; 45:2122-5.
27. Graham DR, Talan DA, Nichols RL, et al. Once-dally, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis 2002; 35:381-9.
28. West M, Boulanger BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003; 25:485-506.